• Explore /
  • Poster
  • / Clinical experience with PSMA-Actinium-225 (Ac-225) radioligand therapy (RLT) in end-stage metastatic castration-resistant prostate cancer (mCRPC) patients.

Clinical experience with PSMA-Actinium-225 (Ac-225) radioligand therapy (RLT) in end-stage metastatic castration-resistant prostate cancer (mCRPC) patients.

Abstract Poster

Authors

null

Maarten Johannes van der Doelen

Radboud University Nijmegen Medical Center, Nijmegen, Netherlands

Maarten Johannes van der Doelen , Niven Mehra , Minke Smits , Inge M. van Oort , Marcel J.R. Janssen , Uwe Haberkorn , Clemens Kratochwil , Winald Gerritsen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, and Testicular Cancers

Track

Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers

Sub Track

Prostate Cancer - Advanced Disease

Citation

J Clin Oncol 36, 2018 (suppl 6S; abstr 344)

DOI

10.1200/JCO.2018.36.6_suppl.344

Abstract #

344

Poster Bd #

D13

Abstract Disclosures

Similar Posters

First Author: A. Oliver Sartor

First Author: Scott T. Tagawa

Poster

2022 ASCO Genitourinary Cancers Symposium

Phase 1 study of P-PSMA-101 CAR-T cells in patients with metastatic castration-resistant prostate cancer (mCRPC).

Phase 1 study of P-PSMA-101 CAR-T cells in patients with metastatic castration-resistant prostate cancer (mCRPC).

First Author: Susan F. Slovin

First Author: Giulio Francolini